Neurologists’ perceptions about the readiness for implementing anti‐amyloid drugs for Alzheimer's disease in Peru

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people worldwide. This situation is particularly severe in low‐ and middle‐income countries, where numerous barriers hinder timely diagnosis and treatment. To date, two monoclonal anti‐amyloid have shown positive results in phase III clinical trials.